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ABSTRACT
Constitutive mobilization of CD34 cells in patients with
primary myelofibrosis (PMF) has been attributed to proteo-
lytic disruption of the CXCR4/SDF-1 axis and reduced
CXCR4 expression. We document here that the number of
circulating CD34/CXCR4 cells in PMF patients, as well
as the cellular CXCR4 expression, was directly related to
CXCR4 mRNA level and that reduced CXCR4 mRNA level
was not due to SDF-1-induced downregulation. To ad-
dress whether epigenetic regulation contributes to defec-
tive CXCR4 expression, we studied the methylation status of
the CXCR4 promoter using methylation-specific polymerase
chain reaction and methylation-specific sequencing in the
JAK2V617F-positive HEL cell line and in CD34 cells. We
found that CD34 cells from PMF patients, unlike those
from normal subjects, presented hypermethylation of
CXCR4 promoter CpG island 1. Following incubation with
the demethylating agent 5-Aza-2-deoxycytidine (5-AzaD),
the percentage of PMF CD34 cells expressing CXCR4
increased 3–10 times, whereas CXCR4 mRNA level in-
creased approximately 4 times. 5-AzaD-treated PMF CD34
cells displayed almost complete reversal of CpG1 island 1
hypermethylation and showed enhanced migration in vitro
in response to SDF-1. These data point to abnormal meth-
ylation of the CXCR4 promoter as a mechanism contributing
to constitutive migration of CD34 cells in PMF. STEM
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INTRODUCTION
Stromal cell-derived factor-1/CXC chemokine ligand 12 (SDF-
1/CXCL12) is a major chemoattractant for normal hematopoi-
etic stem and progenitor cells (HSCs/HPCs). SDF-1 is produced
by endothelial cells, immature osteoblasts, and stromal cells
within the bone marrow (BM) microenvironment, as well as by
other cell types, including CD34 cells themselves [1]. The
canonical receptor for SDF-1 is chemokine receptor 4 (CXCR4),
a member of a family of seven trans-membrane domain recep-
tors coupled to heterotrimeric G1 proteins. Experimental defi-
ciency in SDF-1 or CXCR4 in the embryo resulted in a lethal
phenotype characterized by defective development of cardiac,
gastrointestinal, blood vessel, and central nervous system and in
the lack of BM seeding by HSCs/HPCs and maturing myeloid or
lymphoid cells [2–5]. A role for the SDF-1/CXCR4 axis in
human cancer cell metastatic spread has also been inferred
[6–9].
Firm adhesion of HSCs/HPCs to BM endothelium in a
murine transplantation model was mediated by locally produced
SDF-1 [10], whereas, conversely, SDF-1 administration induced
recruitment of HSCs/HPCs and maturing leukocytes to the
circulation and the spleen [11]. Thus, a positive SDF-1 gradient
is the mechanism (or one of the mechanisms) by which HSCs/
HPCs are normally retained in the BM. The increased mobili-
zation of HSCs/HPCs that occurs following administration of
granulocyte colony-stimulating factor (G-CSF) or chemothera-
peutic agents [12, 13] has been associated with the release of
proteolytic enzymes, such as cathepsin G, neutrophil elastase,
and matrix metalloprotease-9 (MMP-9), which cause SDF-1
degradation and cleavage of the CXCR4 N terminus [12]. How-
ever, a negative correlation was found between the degree of
HSCs/HPCs mobilized to peripheral blood (PB) and CXCR4
expression level in patients receiving chemotherapy plus G-CSF
[14] or G-CSF alone [15]; furthermore, CD34 cells in the BM
of patients on G-CSF displayed lower CXCR4 membrane den-
sity than naı¨ve cells, and the yield of mobilized CD34 cells
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correlated with the proportion of BM CD34/CXCR4 cells
[15]. These data support the contention that mobilization of
CD34 cells is also dependent on the density of CXCR4 on the
cell membrane; accordingly, antagonist-induced desensitization
of CXCR4 caused the egress of HSCs/HPCs from BM to PB
[16]. The mechanisms by which G-CSF affects the expression of
CXCR4 have not been completely elucidated, but at least in part
they depend on proteolytic modifications with functional inac-
tivation of the receptor [13]. However, it has been shown that
G-CSF downregulates CXCR4 in myeloid cells [17] through the
transcriptional repressor growth factor independence-1 (Gfi-1)
[18], whereas modulation of CXCR4 expression at the post-
translational level has been described in both hematopoietic [19]
and nonhematopoietic [7, 20] cells. CXCR4 on the cell surface
of migrating cells is physiologically downregulated upon SDF-1
binding through rapid phosphorylation and internalization of the
receptor [21]. Therefore, mobilization of HSCs/HPCs may be
the consequence of changes in the expression of either SDF-1 or
CXCR4 or both.
Primary myelofibrosis (PMF) is a chronic myeloprolifera-
tive disorder (MPD) characterized by variable changes in blood
cell count, leukoerythroblastosis, splenomegaly, extramedullary
hematopoiesis, and bone marrow fibrosis with extensive angio-
genesis [22]. Constitutive mobilization of CD34 cells in the
PB is one striking characteristic of PMF; the number of these
cells is more than 300 times greater than in healthy subjects and
20–30 times greater than in other MPDs, such as polycythemia
vera and essential thrombocythemia [23]. Abnormal cell mobi-
lization in PMF is not limited to HSCs/HPCs, since more cells
with a CD34/CD133/vascular endothelial growth factor re-
ceptor 2 phenotype have been reported to circulate, preferen-
tially at early phases of the disease [24]; although these cells do
not function as true endothelial progenitor cells and their func-
tion in vessel formation and/or homeostasis is still unknown
[25], they might be involved in the same mechanisms leading to
enhanced mobilization as for the HSCs/HPCs. Mechanisms
underlying the abnormal mobilization of CD34 cells in PMF
probably involve the establishment of a proteolytic environment
causing SDF-1 degradation within the BM [26, 27]. However, it
is likely that abnormalities of CXCR4 also play some role, as
suggested by findings of reduced CXCR4 expression and an
abnormally low CXCR4 mRNA level in PMF CD34 cells [28,
29]. The aim of this study was to address potential mechanisms
for the reduced CXCR4 expression in PMF CD34 cells and its
contribution to the phenomenon of constitutive migration in the
circulation.
SUBJECTS, MATERIALS, AND METHODS
Subjects
This study included a total of 40 PMF patients, 11 normal blood
donors, and 31 volunteer donors of hematopoietic stem cells, of
whom 20 donated BM cells and 11 were mobilized with G-CSF.
Diagnosis of PMF was made according to the criteria identified by
the Italian Consensus Conference [30]; all patients were primary
forms in a typical fibrotic stage of the disease [31], who were
studied at diagnosis or during follow-up, but were cytotoxic agent-
free from at least 1 month. Twenty-four patients were JAK2V617F
mutant (60%) [32], whereas none harbored MPL mutation [33].
Seventy-five percent of the patients were in the low-risk category,
20% in the intermediate category, and 5% in the high-risk category,
according to Lille score [34]. The CD34 cell count in the PB of
PMF patients was 186 179 106 cells per liter (range, 10–379
106 cells per liter). Informed consent from patients and controls was
obtained under an IRB approval study protocol.
Flow Cytometry Analysis of Circulating CD34
Cells
CD34 cells in the PB of PMF patients were enumerated using 50
l of EDTA-anticoagulated blood, after staining with CD45-fluo-
rescein isothiocyanate (FITC)-/CD34-phycoerythrin (PE)-conju-
gated monoclonal antibodies (both from Becton, Dickinson and
Company, San Jose, CA, http://www.bd.com) and 7-aminoactino-
mycin D (BD Pharmingen, San Diego, http://www.bdbiosciences.
com/index_us.shtml) for excluding dead cells in a FACScan flow
cytometer (Becton Dickinson), according to guidelines from the
International Society of Hematotherapy and Graft Engineering [35].
Cell surface expression of CXCR4 (CD184) was determined using
anti-human CD184(CXCR4)-PE antibody (BD Pharmingen) and
the appropriate isotype control. Results were expressed both as the
percentage of CD45/CD34 cells coexpressing CXCR4 and as the
ratio of geometric mean fluorescence intensity (MFI) by dividing
the value of specific antibodies with the corresponding isotype
control antibody. Intracellular CXCR4 staining in cells migrating in
Transwell cells (Corning Costar, Boston, http://www.corning.com/
lifesciences) (described below) was performed after blocking cell
surface CXCR4 with nonconjugated antihuman CXCR4 antibody
(clone 12G5, 10 g/ml, for 1 hour at 4°C). Cells were fixed with
paraformaldehyde and permeabilized with 1% Triton X-100 before
fluorescence-activated cell sorting (FACS) analysis. Data analysis
was performed using WinMDI software (version 2.9; http://facs.
scripps.edu/software.html).
CD34 Cell Purification
BM or PB mononuclear cells were separated over a Ficoll-Hypaque
gradient (Lymphoprep; Nycomed Pharma, Oslo, Norway, http://
www.nycomed.at), and CD34 cells were immunomagnetically
selected (Miltenyi Biotec, Bergisch Gladbach, Germany, http://
www.miltenyibiotec.com) [36]. Purity of the isolated CD34 cell
population was evaluated by flow cytometry after labeling with
PE-HPCA2 anti-CD34 monoclonal antibody (Becton Dickinson).
Aliquots of CD34 cells were immediately resuspended in lysis
buffer for RNA and DNA purification or used in culture.
Ex Vivo Short-Term Incubation of CD34 Cells
Purified CD34 cells were cultured at 105 cells per milliliter in
Iscove’s modified Dulbecco’s medium (IMDM; Bio Whittaker)
containing 10% fetal calf serum (FCS; HyClone, Logan, UT, http://
www.hyclone.com) and incubated at 37°C and 5% CO2 in a hu-
midified atmosphere for 4 hours. Cells were then exposed for
variable times up to 48 hours to different agents, including cyto-
kines (SDF-1, transforming growth factor- [TGF-], and interfer-
on- [IFN-]; all from Peprotech, Rocky Hill, NJ, http://www.
peprotech.com) and the hypomethylating agent 5-Aza-2-
deoxycytidine (5-AzaD; Sigma-Aldrich, Milano, Italy, http://www.
sigmaaldrich.com). Parallel cultures without added cytokines or
5-AzaD were prepared in each experiment as control. At the end of
incubation, cells were collected and either processed directly for
FACS analysis or nucleic acid extraction, or washed in fresh me-
dium for use in migration experiments.
Cell Lines
The human erythroleukemia HEL and K562 cell lines and the
myeloid HL60 cell line were purchased from the American Type
Culture Collection (Manassas, VA, http://www.atcc.org). The cells
were maintained in IMDM supplemented with 10% FCS.
Real-Time Quantitative Polymerase Chain Reaction
Determination of CXCR4 mRNA Level
Total RNA was extracted using Trizol (Invitrogen, Paisley, U.K.,
http://www.invitrogen.com); RNA concentration and purity/integ-
rity were determined using NanoDrop technology (ND-1000 spec-
trophotometer; NanoDrop, Wilmington, DE, http://www.nanodrop.
com). cDNA was reverse-transcribed from 100 ng of total RNA
obtained from purified CD34 cells using the High Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA, http://www.
appliedbiosystems.com). TaqMan polymerase chain reactions
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(PCRs) were carried out with the TaqMan Universal PCR Master
Mix, using TaqMan Gene Expression Assays (HS-00607978 for
CXCR4; Applied Biosystems), by means of the ABI Prism 7300 HT
Sequence Detection System (Applied Biosystems). Assays were
performed in quadruplicate. Gene expression profiling was achieved
using the comparative cycle threshold (CT) method of relative
quantitation using VIC-labeled RNaseP probe as the housekeeping
gene (Applied Biosystems) (CT).
Methylation-Specific PCR and Methylation-Specific
Sequencing Analysis of CXCR4 Promoter
Methylation Status
To determine the location of CpG islands in the promoter region of
CXCR4, we used the MethPrimer software (http://www.urogene.
org/methprimer/index1.html); five CpG islands were identified, and
primers for each CpG island were designed to be used in a meth-
ylation-specific polymerase chain reaction (MSP) assay (reported in
supplemental online Fig. 1). We also designed primers for use in a
methylation-specific sequencing (MSS) assay (described below),
which allowed the amplification of a 230-nucleotide region within
CpG island 1 containing 22 individual CpG dinucleotides. In brief,
1 g of DNA obtained from CD34 cells or cell lines was treated
with sodium bisulfite to induce conversion of unmethylated cyto-
sine to uracil (Epitect Bisulfite kit; Qiagen, Hilden, Germany,
http://www1.qiagen.com). The CpG methylase SssI from Spiro-
plasma sp., strain MQ1 (New England Biolabs, Beverly, MA,
http://www.neb.com), was used to produce fully methylated meth-
ylate DNA from HL60 cells (positive control). MSP was performed
using primers specific for either the methylated or unmethylated
DNA under the following conditions for TaqGold polymerase (Ap-
plied Biosystems): 94°C for 13 minutes followed by 40 cycles at
94°C for 30 seconds, 59°C or 60°C (for methylated and unmethyl-
ated CXCR4, respectively) for 30 seconds, and 72°C for 30 seconds.
Amplicons were resolved in 3% agarose gel and visualized by
ethidium bromide staining. Bisulfite-modified DNA was also used
as direct template for MSS. PCR conditions were as follows: 94°C
for 13 minutes; 30 cycles consisting of 30 seconds at 94°C, 30
seconds at 56°C, and 30 seconds at 72°C; and 10 minutes at 72°C.
The primer sequences were as follows: forward primer, 5-gaggg-
ggaaagtattgtttg-3; reverse primer, 5-aaacttacacaaaatcactcattca-3.
Amplicons were subjected to bidirectional sequencing on an ABI
Prism 3730 DNA Analyzer (Applied Biosystems).
In Vitro Migration Assay for CD34 Cells
For these experiments, 2  105 purified CD34 cells were seeded
in 500 l of IMDM supplemented with 10% FCS in the absence
(control) or in the presence of 1 M 5-AzaD for 12 hours. At the
end of incubation, cell aliquots were labeled with anti-CD34 FITC
and anti-human CD184(CXCR4) PE to evaluate changes in CXCR4
content upon 5-AzaD exposure. Immediately before migration as-
say, CD34 cells were washed in serum-free media, resuspended in
100 l of IMDM, and loaded into Transwell filters (5 m pore;
Transwell, 24-well cell clusters), which were then carefully trans-
ferred to wells containing 500 l of serum-free medium supple-
mented or not (for calculation of passive diffusion) with 125 ng/ml
recombinant hSDF-1. Plates were incubated at 37°C in 5% CO2
for 3 hours, and then the upper chamber was carefully removed and
cells in top and bottom chambers were counted; the percentage of
CD34 cells undergoing migration in samples treated or not with
5-AzaD was calculated after subtracting passive diffusion.
Statistical Analysis
Comparison between groups was performed by the Mann-Whitney
U test or Fisher test as appropriate, using the SPSS software
(StatSoft, Inc., Tulsa, OK, http://www.statsoft.com), GraphPad In-
Stat software (GraphPad Software, Inc., San Diego, http://www.
graphpad.com), or Origin software (version 7.5; OriginLab,
Northampton, MA, http://www.originlab.com) for computation.
The chosen level of significance from two-sided tests was p  .05.
RESULTS
CXCR4 Expression in PMF CD34 Cells Correlates
with CXCR4 mRNA Level
The expression of membrane CXCR4 in CD34 cells from PB
of PMF patients was determined by flow cytometry (FACS) and
compared with normal different sources, which included un-
stimulated peripheral blood (uPB) and G-CSF-mobilized pe-
ripheral blood (mPB) and BM aspirates. As shown in Figure 1A
and 1B, the frequency of CD34 cells coexpressing CXCR4 in
the PB of PMF patients was significantly lower than in normal
samples (p  .01 compared with uPB or BM cells; p  .05
compared with mPB). In normal samples, CD34CXCR4
cells progressively decreased from a median of 68.3% of all
CD34 cells in the BM to 54.3% in uPB and to 21.5% in mPB.
Also, the density of CXCR4 molecules, expressed as the MFI,
was significantly lower in PMF CD34 cells compared with
normal uPB or BM CD34 cells but not compared with mPB
CD34 cells (Fig. 1B). Purified PMF CD34 cells expressed
significantly lower CXCR4 mRNA level than normal cells from
all other sources; the highest and lowest mRNA levels were
measured in CD34 cells from control BM and PMF PB,
respectively, differing on the order of 4.9 CT (Fig. 1B). On the
basis of the assumption that in optimized real-time quantitative
(RTQ) PCR experiments a CT n  3.3 corresponds to a
10-fold difference in mRNA level [37], it was calculated that
CXCR4 mRNA expression in PMF CD34 cells was 	40-fold
lower than in normal BM CD34 cells. Both the frequency of
circulating CD34/CXCR4 cells and the CXCR4 MFI in PMF
patients were correlated with CXCR4 mRNA level, as shown in
Figure 1C and 1D, respectively. The percentage of CD34 cells
coexpressing CXCR4, the CXCR4 MFI, and the level of CXCR4
mRNA were all similar in patients harboring the JAK2V617F
mutation and those not harboring it (not shown in detail).
Reduced CXCR4 mRNA Level Is Not Due to
SDF-1-Induced Downregulation
SDF-1 level has been found to be significantly increased in the
BM microenvironment and in plasma of PMF patients [28, 38];
although downregulation of CXCR4 expression on the cell
membrane would be expected because of its physiologic inter-
nalization upon SDF-1 cross-linking, we also asked whether the
reduced CXCR4 mRNA level observed in PMF CD34 cells
could follow ligand binding. To this end, we first determined the
expression pattern of CXCR4 and CXCR4 mRNA in three
different hematopoietic cell lines: the HEL cell line, which
harbors JAK2 V617F mutation; the BCR/ABL-positive K562
cell line; and the PML-RAR-positive HL-60 cell line. We
found that K562 cells were virtually negative for CXCR4 ex-
pression, whereas almost all HL60 cells expressed CXCR4 at a
high level (MFI  1.9); on the other hand, approximately 25%
(range, 9.2%–49.3%) of HEL cells were CXCR4 dim (MFI 
1.2) (Fig. 2). The level of CXCR4 mRNA mirrored the results of
FACS analysis (Fig. 2B); CXCR4 mRNA was virtually unde-
tectable in K562 cells, highly expressed in HL60 cells, and
expressed at intermediate level, approximately 15-fold lower, in
HEL cells.
HEL cells were exposed to increasing concentration of
SDF-1 for 3–24 hours. Starting as soon as after 3 hours of
incubation, we observed a dose-dependent decline of membrane
CXCR4 that became undetectable in the presence of 500 ng/ml
SDF-1 (Fig. 3A, 3B); on the contrary, CXCR4 mRNA level
remained stable (Fig. 3B). CXCR4 was similarly downregulated
in the presence of 500 ng/ml SDF-1 in CD34 cells from normal
uPB or PMF PB; again, no concurrent modification of mRNA
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level was observed (Fig. 3C–3E). We concluded that SDF-1-
induced decrease of CXCR4 expression in HEL cells and in
CD34 cells was due to ligand-induced internalization of the
receptor but did not involve CXCR4 transcription. We also
evaluated the effect of TGF-, whose level is increased in PMF
[39] and supposedly involved in disease pathogenesis [40, 41],
and of IFN-, which was shown to downregulate CXCR4
mRNA in lymphocytes and neutrophils [42, 43]; we observed
that neither cytokine induced modification of CXCR4 expres-
sion or of CXCR4 mRNA level in normal uPB- and PMF
PB-derived CD34 cells (supplemental online Fig. 2).
The CXCR4 Promoter Methylation Status Correlates
with CXCR4 mRNA Level
Since epigenetic mechanisms have been shown to contribute to
regulated expression of CXCR4 in solid cancer cell lines [44–
46], we asked whether this mechanism might also be involved in
the abnormally low CXCR4 expression in PMF CD34 cells.
The promoter region of CXCR4 contains five CpG islands
(supplemental online Fig. 1); an MSP assay on bisulfite-treated
DNA was designed to evaluate methylation status of each of
these CpG islands, whereas MSS was used for sequencing a
CpG dinucleotide-rich region within CpG island 1. In the first
set of experiments, we used cell lines. We found that CpG 1 and
5 were partially methylated in HEL cells, whereas K562 cells
had preferential representation of the methylated allele corre-
sponding to CpG island 1, 3, and 5; on the other hand, there was
no evidence for methylated alleles in HL60 cells (Fig. 4A). By
using MSS, we confirmed that HL60 cells had 100% unmeth-
ylated cytosine compared with 40%  8% and 74%  16%
in HEL and K562 cells, respectively (mean  SD of three
determinations; p  .01 for both compared with HL60 cells)
(Fig. 4B).
The methylation status of CXCR4 promoter was evaluated in
CD34 cells purified from the BM (n  4) or mPB (n  4) of
healthy controls but not from uPB because of the insufficient
number of purified cells that could be obtained. According to
MSP, we found that all CpG islands in the CXCR4 promoter of
BM-derived CD34 cells were in an unmethylated status,
whereas in CD34 purified from mPB, a faint band correspond-
ing to the methylated allele of CpG island 1 could be observed
(Fig. 5A). On the other hand, all 18 PMF patients evaluated
displayed comparable representation of methylated and unmeth-
ylated alleles corresponding to CpG island 1, with faint evidence
of a methylated allele for CpG island 5 also (patients 3, 4, and
7) (Fig. 5A). By using MSS analysis, we calculated that 25% 
13% of cytosine residues in PMF CD34 cells were methylated,
compared with none in normal BM CD34 cells and 9%  4%
Figure 1. Frequency of CD34CXCR4
cells in the PB of PMF patients and CXCR4
cellular expression in CD34 cells are cor-
related to CXCR4 mRNA level. The fre-
quency of CD34 cells coexpressing
CXCR4 was determined by fluorescence-
activated cell sorting analysis in the PB of
PMF patients (n  40), in the PB of healthy
subjects in the steady state (uPB; n  11) or
after granulocyte colony-stimulating factor
priming (mPB; n  11), and in BM aspirate
from volunteer donors (n  20). A typical
histogram for these different cell sources is
presented in (A), and median value (range)
of CD34CXCR4 cells and the CXCR4
expression expressed as the MFI are re-
ported in (B). CXCR4 mRNA level was mea-
sured in purified CD34 cells by real-time
quantitative polymerase chain reaction and
expressed as CT after being normalized to
RNaseP as the housekeeping gene. Please
note that higher CT values indicate lower
mRNA content. , p  .05; , p  .01. The
relationship between percentage of circulat-
ing CD34CXCR4 or the CXCR4 MFI
and the level CXCR4 mRNA concurrently
measured in purified CD34 cells is pre-
sented in (C) and (D), respectively. In both
instances, the correlation between the two
variables was statistically significant at p 
.01. Abbreviations: BM, bone marrow; MFI,
mean fluorescence intensity; mPB, mobi-
lized peripheral blood; PB, peripheral blood;
PMF, primary myelofibrosis; uPB, unstimu-
lated peripheral blood.
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in mPB (p  .01 for both). These data, together with those
presented in Figure 1, suggested that in CD34 cells from
healthy subjects and PMF patients, as was observed in cell lines,
the level of CXCR4 mRNA is correlated with the methylation
status of CpG island 1 of the CXCR4 promoter.
Hypomethylating Agent 5-AzaD Reverts Abnormal
Methylation of CXCR4 Promoter and Increases
CXCR4 Expression
The above results prompted us to evaluate the effect of dem-
ethylating agent 5-AzaD on the transcriptional activity of
CXCR4. First, we evaluated different concentrations of the
agent, incubation times, and cell densities in cultures of HEL
cells (not shown in detail); the best conditions were represented
by a 1.0 M concentration of 5-AzaD for 6–48 hours of
incubation, using cells that had been synchronized in serum-free
medium for 12–16 hours. The number of HEL cells expressing
CXCR4 in synchronized cultures was lower (median, 15%;
range, 9%–19%) than in passage cultures (comparison shown in
Fig. 2), allowing better appreciation of any changes induced by
drug treatment. In synchronized HEL cells that had been ex-
posed to 5-AzaD for 24 hours, the percentage of CXCR4 cells
increased up to a median of 47% (range, 30%–58%; p  .01 vs.
untreated cultures (Fig. 4C, 4D). There was no further increase in
the percentage of CXCR4 cells at 48 hours of culture, but cell
toxicity in the presence of 5-AzaD became significant (25% 
10% of the cells were trypan blue-positive at that time point).
The level of CXCR4 mRNA was measured by RTQ-PCR at
different times after drug exposure, from 2 to 48 hours. We
observed a statistically significant increase of CXCR4 mRNA in
a very narrow time interval, peaking at 8 hours of incubation and
returning to pretreatment level at 24 hours; the mean CXCR4
mRNA increase at 8 hours was 6.1 ( 0.9)-fold compared with
control cultures (p  .01; Fig. 4E). We evaluated whether
enhanced transcription of CXCR4 after 5-AzaD exposure was
associated with changes of promoter methylation status; to this
end, cells were incubated with 5-AzaD for 24 hours, and bisul-
fite-treated DNA was analyzed using both MSP and MSS. As
shown in Figure 4F and 4G, we observed a significant reduction
in the proportion of methylated allele corresponding to CpG
island 1, with no appreciable modification of CpG island 5,
whereas the percentage of methylated cytosine using MSS anal-
ysis decreased from 40%  12% to 14%  8% (n  3 exper-
iments; p  .003). Overall, these results suggested that the
CXCR4 mRNA level in HEL cells was correlated mainly with
the methylation status of CpG island 1, whereas the role of CpG
island 5, if any, could not be clearly ascertained.
When purified CD34 cells from PMF patients were incu-
bated for 8–24 hours with 1 M 5-AzaD, a 3.9-fold median
increase (range, 3.5–10) in the number of CD34 cells coex-
pressing CXCR4 was observed at 12 hours of incubation (p 
.001 vs. untreated cells) (Fig. 6A, 6B); concurrently, levels of
CXCR4 mRNA were already increased 3.7-fold (range, 3.1–4.1)
at 8 hours (Fig. 6B). Changes in methylation status of CXCR4
promoter were analyzed using MSP and MSS and are presented
in Figure 6C. In all patients evaluated, MSP revealed the dis-
appearance of the amplicon corresponding to the methylated
allele of CpG island 1, whereas in cases where a methylated
allele of CpG island 5 was present (i.e., patients 2, 3, and 5), no
significant modification after 5-AzaD incubation could be dem-
onstrated. These data were corroborated by the results of MSS
analysis that showed a complete (as was the case for patients 1
and 3) or more than 70% (i.e., patients 4 and 5) reduction in
methylated CpGs within the 230-base pair fragment correspond-
ing to CpG island 1.
5-AzaD Treated PMF CD34 Cells Showed
Enhanced Migrating Properties
To assess the functional consequence of increased CXCR4
expression in PMF CD34 exposed to 5-AzaD, we performed
an in vitro migration assay in response to SDF-1. Purified
CD34 cells from eight PMF patients were incubated with or
without 5-AzaD, and their migration in response to a gradient of
SDF-1 added to the lower chamber was assessed at 3 hours.
After subtracting passive diffusion (i.e., the number of CD34
cells that migrated to the lower chamber in the absence of
SDF-1), the percentage of CD34 cells migrating to the lower
chamber in response to SDF-1 increased from a mean ( SD) of
6.3%  1.1% in controls to 23.2%  8.9% in CD34 cells
preincubated with 5-AzaD (p  .007). We then measured the
expression of membrane and intracellular CXCR4 in nonmigrat-
ing (upper chamber) and migrating (lower chamber) cells after
5-AzaD treatment in four experiments. Although we observed
no change in the ratio of membrane versus intracellular CXCR4-
associated fluorescence in the upper-chamber cells, those that
had migrated presented a median fourfold increase in the rela-
tive amount of intracellular versus membrane CXCR4 (data not
shown in detail), indicating receptor internalization upon SDF-1
binding.
DISCUSSION
The peripheral blood of PMF patients contains more HSCs/
HPCs, including more immature progenitors capable of repop-
ulating the BM of irradiated mice [27]. Stem cell mobilization is
a normal phenomenon in healthy subjects that can be magnified
after administration of cytokines, particularly G-CSF, and/or
Figure 2. Expression of CXCR4 and level of CXCR4 mRNA in three
hematopoietic cell lines. Expression of CXCR4 on the membrane of
HL60, K562, and HEL cells was measured by fluorescence-activated
cell sorting and expressed as the percentage of CXCR4 cells and as the
CXCR4 MFI. A typical histogram is presented in (A), and median value
(range) from at least three individual determinations is reported in (B).
The CXCR4 mRNA level was measured by real-time quantitative poly-
merase chain reaction and expressed as CT after being normalized to
RNaseP as the housekeeping gene. Please note that higher CT values
indicate lower mRNA content. Abbreviation: MFI, mean fluorescence
intensity.
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chemotherapeutics and is mediated by neutrophil-released pro-
teases disrupting the adhesive interaction of HSCs/HPCs with
the microenvironment. As a matter of fact, elevated levels of
neutrophil elastase, MMP-9, and soluble vascular cell adhesion
molecule 1 were found in plasma of PMF patients and correlated
with the number of circulating CD34 cells [26]. Furthermore,
it has been observed that both the number of CD34 cells
coexpressing CXCR4 and the CXCR4 cellular expression were
significantly reduced in PMF, and such abnormalities have been
attributed to reduced transcriptional activity of CXCR4 [26, 28,
Figure 3. Downregulation of CXCR4 expression induced by SDF-1 in HEL or CD34 cells does not involve changes in CXCR4 mRNA level. HEL
cells (A) or purified CD34 cells from the peripheral blood from primary myelofibrosis (PMF) patients (C) were incubated with SDF-1 up to 500
ng/ml, as indicated in each plot. Variation of CXCR4 membrane expression by fluorescence-activated cell sorting analysis at 12 h in a typical
experiment is depicted in (A) and (C) for HEL cells and PMF CD34 cells, respectively; the percentage of CXCR4 cells is reported inside each
plot. The mean ( SD) percentage variation in the number of CXCR4 cells, calculated from pooled experiments with HEL cells (n  3) or CD34
cells purified from PMF patients (n  5) or normal donors (n  5), after being exposed to 500 ng/ml SDF-1 for different times, is shown (square
symbols) in (B), (D), and (E), respectively. Concurrent modification of CXCR4 mRNA level measured by real-time quantitative polymerase chain
reaction (circle symbols) is presented in (B) for HEL cells, (D) for PMF patients, and (E) for CD34 cells obtained from unstimulated peripheral
blood. Abbreviations: h, hours; Max, maximum; PE, phycoerythrin.
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Figure 4. CXCR4 promoter is differentially M in HL60, K562, and HEL cells and is sensitive to the hypomethylating activity of 5-AzaD. In (A),
methylation-specific polymerase chain reaction (MSP) was performed using primers specific for the M or u sequence of each of the five CpG islands
located in the CXCR4 promoter; in (B), methylation-specific sequencing (MSS) was performed on a 230-base pair region of CpG island 1. Filled
circles indicate M cytosine, and empty circles indicate u cytosine. The SssI-treated DNA from HL60 cells served as positive Ctr (all M cytosines).
In (C) and (D), synchronized HEL cells were exposed to 5-AzaD for 24 h, and the percentage of CXCR4 cells, as well as the CXCR4 MFI, was
measured by fluorescence-activated cell sorting. In (C), a typical experiment is presented, and cumulative results from four experiments are presented
in (D). , p  .01 versus untreated cells. Boxes represent the interquartile range that contains 50% of the values, the horizontal line in the box marks
the median, the small square inside indicates mean value, and bars show the range of values. The level of CXCR4 mRNA was measured by real-time
quantitative polymerase chain reaction in HEL cells exposed to 1 M 5-AzaD for 2–48 h, and the mean  SD value from five experiments is
presented in (E). The CXCR4 mRNA level measured at 8 h in the presence of 5-AzaD was significantly different from all other time points (p .001).
The methylation status of the CXCR4 promoter was evaluated after a 24 h of exposure to 5-AzaD using both MSP (F) and MSS (G) (filled circles
indicate M cytosine, and empty circles indicate u cytosine). Abbreviations: 5-AzaD, 5-Aza-2-deoxycytidine; Ctr, control; h, hours; M, methylated;
MFI, mean fluorescence intensity; u, unmethylated.
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29]; accordingly, CXCR4 was one of the mostly downregulated
genes in transcriptome analysis of PMF CD34 cells [29].
Overall, these findings suggested that abnormal CD34 cell
circulation in PMF is facilitated not only by increased proteol-
ysis of target molecules, including SDF-1 and CXCR4, but also
by defective regulation of CXCR4.
Understanding of the molecular mechanisms underlying
PMF has been facilitated by the recent discovery of recurrent
molecular abnormalities in MPDs [47, 48]. Sixty percent of
PMF patients present the JAK2V617F mutation [49–53],
whereas 8% of JAK2 wild-type harbors genetic abnormalities in
MPL [33, 54, 55]. However, these mutations are also displayed
by patients with other MPDs, suggesting that additional events
are probably involved in the pathogenesis of disease [56]. In
recent years, evidence has accumulated for a critical role of
epigenetics in cell transformation toward the neoplastic pheno-
type through aberrant gene transcription [57]. Epigenetics may
be defined as the interplay of DNA methylation, histone mod-
ifications, and expression of noncoding RNAs [58], which to-
gether regulate gene expression [59] according to tissue- and
cell-specific patterns [60]. A common epigenetic change in
cancer is represented by aberrant hypermethylation of CpG
islands in gene promoters, with reduced or absent transcription
of the genes [57]. Transcriptional silencing of hypermethylated
genes also depends on synergy between methylation and activity
of histone deacetylases (HDAC) [61]. The presumptive role of
gene silencing in oncogenesis [62, 63] and the availability of
drugs capable of modifying methylation status and/or histone
acetylation level [64] have fostered efforts to identify such
hypermethylated loci in cancer cells [65, 66]. However, knowl-
edge about epigenetic abnormalities in PMF, and more in gen-
erally in MPDs, is still scanty. No hypermethylation of the
promoters of several cell cycle control genes was found in PMF
patients [67], whereas hypermethylation of p15ARF and
p16INK4A accompanied leukemic transformation in a few cases
[68]. Similarly, reduced expression of the receptor RII for
TGF- was not attributed to abnormal methylation of gene
promoter [69, 70]. On the other hand, evidence of hypermeth-
ylation of RAR2 promoter-2 was found in 89% of 18 patients
with PMF who presented reduced expression of RAR2, a
candidate tumor suppressor gene [71], although this was not
confirmed in another study [72]. Hypermethylation of SOCS-1
and of SOCS-3 has been described recently [72, 73].
In the experiments presented herein, we have identified
CXCR4 as a target of epigenetic regulation because of abnormal
methylation in PMF cells. First, we extended a previous obser-
vation that reduced expression of CXCR4 in PMF CD34 cells
depends on the level of CXCR4 transcription. Second, we pro-
vided evidence that CXCR4 promoter is hypermethylated in ex
vivo-purified PMF CD34 cells from patients and that treat-
ment with 5-AzaD reverted such abnormal hypermethylation,
promoting gene transcription and enhancing CXCR4 expres-
sion, resulting overall in improved migration of CD34 cells in
response to an SDF-1 gradient. Although definite proof that
increased CXCR4 expression in 5-AzaD-exposed PMF CD34
cells might result in their enhanced retention in the BM would
require in vivo experiments in immunodeficient mice, we inter-
pret the results of the in vitro migration assay as supportive of
that possibility.
Results of this study might have relevance for PMF from
two perspectives. First, they identified abnormalities of CXCR4
as a protease-independent mechanism for the constitutive mo-
bilization of HSCs/HPCs. Second, observed effects of 5-AzaD
in the culture of CD34 cells forecast therapeutic relevance of
targeting gene methylation in the therapeutic approach to PMF.
Additional evidence that abnormal epigenetic regulation is con-
current with pathophysiology of PMF has recently been pro-
vided by Shi et al., who observed profound changes in PMF
CD34 cells exposed to chromatin-modifying agents, including
5-AzaD and trichostatin [74]. In a semisolid assay, the propor-
tion of clonogenic HPCs harboring JAK2V617F was signifi-
cantly reduced when CD34 cells had been exposed to the
agents. Furthermore, the number of cells expressing CXCR4
that appeared after 9 days in cultures established with treated
CD34 cells was significantly higher than that in control cul-
tures [74]. The designs of the above study and our own are
different, but the information is compellingly complementary.
The long-term culture design used by Shi et al. [74] after
exposure of CD34 cells to the chromatin-modifying agents
likely resulted in preferential elimination of mutant cells and
Figure 5. Analysis of methylation status of
CXCR4 promoter in CD34 cells from PMF
patients and healthy controls (mPB or BM).
In (A), MSP was performed using primers
specific for the M or u sequence of each of
the five CpG islands located in the CXCR4
promoter; in (B), MSS was performed on a
230-base pair region of CpG island 1. Filled
circles indicate M cytosine, and empty cir-
cles indicate u cytosine. Representative pic-
tures of one of four normal controls each for
BM and mPB and of 8 of 18 PMF patients
analyzed are shown. Abbreviations: BM,
bone marrow; M, methylated; mPB, granu-
locyte colony-stimulating factor-mobilized
peripheral blood; PMF, primary myelofibro-
sis; u, unmethylated.
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expansion of residual normal cells expressing physiologic level
of CXCR4. On the other hand, the effects we observed in the
short-term time in our experimental scheme are in support of a
direct effect of 5-AzaD on the abnormal methylation status of
CXCR4 in progenitors. Overall, this would suggest that using
demethylating agents in PMF, eventually in association with
HDAC, might potentially have a double action mechanism
against clonal progenitors, both inhibiting their growth and
facilitating the re-emergence of normal progenitors, and reacti-
vating abnormally repressed genes.
Some open questions still remain that might be addressed in
future studies. One concerns possible relationships between
downregulation of CXCR4 and abnormal tyrosine kinase activ-
ity due to JAK2V617F mutation or other functionally equivalent
molecular abnormalities. In this work, we did not find differ-
ences in CXCR4 expression in PMF CD34 cells depending on
the JAK2 mutational status, confirming previous results in
CD34 cells [28]. On the other hand, the fact that CXCR4
mRNA level was significantly reduced in the granulocytes of
PMF patients harboring a high mutant allele burden [29]
would suggest additional regulatory levels dependent on the
cell hierarchy or lineage belonging. In this regard, it is of
interest that expression of p210/BCR-ABL has been shown to
impair CXCR4 signaling through two different mechanisms
depending upon its level of expression; at a low level of p210
expression, a signaling defect predominated without obvious
modification of CXCR4 expression, whereas a higher level of
p210 induced a marked downregulation of CXCR4 due to
decreased CXCR4 transcription [75]. In addition, it might be
worthwhile to investigate possible effects of defective
CXCR4 expression on the HSC/HPC proliferation and dif-
ferentiation in PMF. In fact, in addition to regulating migra-
tion and homing of HSCs/HPCs, SDF-1 has an autocrine/
paracrine effect by promoting survival of normal CD34
cells through suppression of apoptosis and recruitment of
quiescent G0 cells in G1 phase of the cell cycle [1]. Further-
more, SDF-1 intervenes in the regulation of proliferation and
maturation of progenitors committed to megakaryocytopoi-
Figure 6. The hypermethylated status of CXCR4 promoter in CD34 cells from primary myelofibrosis (PMF) Pt is sensitive to the hypomethylating
activity of 5-AzaD. CD34 cells purified from peripheral blood of PMF Pts were incubated for 8–24 hours with 1 M 5-AzaD. In (A), a typical
fluorescence-activated cell sorting analysis of the expression of CXCR4 by CD34 cells is presented; the percentage of CD34CXCR4 cells, and
the CXCR4 MFI, after exposure to 5-AzaD for 24 hours is reported inside each plot. Two representative Pts, corresponding to those also presented
in (C), are shown. Cumulative results obtained in 10 Pts are presented in (B) and expressed as fold increase of CD34 cells coexpressing CXCR4
versus untreated cells. The value measured in cultures containing 5-AzaD was significantly different from Ctr cultures at p  .01. Fold change in the
level of CXCR4 mRNA measured by real-time quantitative polymerase chain reaction at 8 hours of incubation with 5-AzaD of PMF CD34 cells is
presented in (B) (from a total of nine individual determinations). Boxes represent the interquartile range that contains 50% of the subjects, the
horizontal line in the box marks the median, the small square inside indicates mean value, and bars show the range of values. The effect of 5-AzaD
treatment on the methylation status of CXCR4 promoter in PMF CD34 cells was evaluated using MSP (C) and MSS (filled circles indicate M
cytosine, and empty circles indicate u cytosine); representative results in five of nine PMF Pts evaluated are shown. Abbreviations: 5-AzaD,
5-Aza-2-deoxycytidine; Ctr, control; M, methylated; MFI, mean fluorescence intensity; Pt, patient; u, unmethylated.
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esis [76 –79]; these progenitors are the most obviously in-
volved hematopoietic cell lineage in PMF.
CONCLUSION
Overall, our data indicate that an abnormal degree of methyl-
ation of the CXCR4 promoter might contribute to the constitu-
tive migration of CD34 cells in PMF patients. However, it
might also be anticipated that defective expression of CXCR4 in
PMF CD34 cells might also influence other functional aspects
of the cells in addition to their unique migration and homing
properties.
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